Clinical trials: Prostate Cancer, not yet recruiting
Prostate Cancer
Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness
The primary objective of the trial is to compare the impact and safety of delayed salvage therapy (dSRT, i.e., SRT initiated at PSA values of 0.4-0.5 ng/ml) to those of early salvage therapy (eSRT, i.e., at PSA levels of 0.2…
- Trial name
- ESTABLISH (NCT05232578)
- Testing
- Early salvage radiotherapy (eSRT), Delayed Salvage radiotherapy (dSRT)
- Volunteers
- 380 people
- Sponsor
- General University Hospital, Prague
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
This is a multicenter, randomized, open-label phase 2 study for men with metastatic hormone-sensitive prostate cancer. About 254 participants will first receive 6 months of darolutamide plus androgen deprivation therapy.
- Trial name
- PSMA-DaroRT (NCT07649421)
- Testing
- Stereotactic Body Radiotherapy (SBRT), Darolutamide 600 mg twice daily, Androgen Deprivation Therapy (ADT)
- Where
- China
- Volunteers
- 254 people
- Sponsor
- West China Hospital
Prostate Cancer, Recurrent Prostate Cancer
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression in patients with prostate cancer belonging to the intermediate unfavorable or high risk group, who have low…
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent
- Trial name
- NCT07593079
- Testing
- Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer Patients, Androgen Deprivation Therapy
Effects of Combined Training in Prostate Cancer Patients
Prostate cancer is the most prevalent type among men in Brazil, after non-melanoma skin cancer. One of the main treatment approaches is androgen suppression therapy (AST), which, although effective in controlling tumor growth…
- Trial name
- Proactive (NCT07680920)
- Testing
- Combined training
- Volunteers
- 46 people
- Sponsor
- Universidade Federal de Santa Catarina
Urethral Stricture, Bladder (Urothelial, Transitional Cell) Cancer
The Impact of Age and Sex on Anticipated and Experienced Pain in First-Time Outpatient Flexible Cystoscopy
Cystoscopy is a procedure frequently performed in daily urological practice for the diagnosis of various urological conditions, including bladder tumors, benign prostatic hyperplasia, recurrent cystitis, and urethral strictures.
- Conditions
- Urethral Stricture, Bladder (Urothelial, Transitional Cell) Cancer, Benign Prostate Obstruction (BPO)
- Trial name
- PAINCYST (NCT07375641)
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Kayseri Education and Research Hospital
Urinary Tract Infection, Prostatitis
FOsfomycin for Male Urinary Tract Infection
Male urinary tract infections (MUTI) are often less recognised compared to those in women. French clinical guidelines practices recommend the use of antibiotics called fluoroquinolones, which are highly effective in treating…
- Conditions
- Urinary Tract Infection, Prostatitis, Cystitis
- Trial name
- FOMUTI (NCT06822751)
- Testing
- Fosfomycun-trometamol
- Where
- France
- Volunteers
- 138 people
- Sponsor
- University Hospital, Rouen
Localised Prostate Cancer
Microwave Intervention Under Local Anesthesia
This study aims to evaluate the feasibility of performing a focal Targeted Microwave Ablation (TMA) procedure using Koelis TMA® under local anesthesia in patient with localized prostate cancer.
- Trial name
- MILA (NCT07412275)
- Testing
- Local Anesthesia (lidocaine hydrochloride)
- Where
- 2 sites in Belgium, France
- Volunteers
- 20 people
- Sponsor
- Koelis
Prostate Cancer
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer
This is a prospective, open-label, multicenter, Phase I/II exploratory diagnostic imaging study to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics, biodistribution, imaging characteristics, and…
- Trial name
- COPRA424 (NCT07765940)
- Testing
- [⁶⁴Cu]Cu-RAX301 Injection
- Volunteers
- 52 people
- Sponsor
- RadAlliance Therapeutics, Inc
Prostate Cancer (Adenocarcinoma)
Evaluation of the PROSTia Test in Patients Undergoing Prostate Biopsy
The investigators are interested here in the contribution of a new prostate cancer screening method and, more specifically, in the new and somewhat futuristic approach of artificial intelligence in the development of new, more…
- Trial name
- PROSTIA- BP (NCT06931496)
- Testing
- PROSTia test
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Central Hospital, Nancy, France
Prostate Cancer
Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with…
- Trial name
- NCT07795268
- Testing
- 177Lu-NYM032 injection, Best supportive/best standard of care
- Volunteers
- 600 people
- Sponsor
- Norroy Bioscience Co., LTD
Prostatic Neoplasms, Prostate-Specific Antigen
Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy
This study investigates the prognostic value of dynamic changes in Prostate-Specific Antigen (PSA) levels found in the peritoneal drainage fluid after radical prostatectomy.
- Trial name
- NCT06608225
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Prostate CA
Prostate MRI Analysis by Radiologists and Artificial Intelligence - Disease Identification and Guided Management
Prostate cancer is the most common male cancer in 112 countries and makes up 7% of global cancer cases, and is the second leading cause of cancer-related deaths in men.
- Trial name
- PARADIGM (NCT07647445)
- Testing
- AI (Lucida Pi) interpretation, Radiologist interpretation
- Volunteers
- 500 people
- Sponsor
- University College, London
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer
This phase 1b trial is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) and pembrolizumab in patients with metastatic castration…
- Trial name
- LumOnate (NCT07090369)
- Testing
- Olaparib (300 mg BID), Pembrolizumab, 177Lu-PSMA-I&T
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer
MRI-guided Ultrahypofractionated SBRT Prostate Program
The goal of this clinical trial is to learn if the use of MRI-guided asymmetric ultrahipofractionated irradiation (2 fractions with dose increase in the tumor areas and dose sparing in urethra, rectum and neurovascular bundles)…
- Trial name
- NCT07132658
- Testing
- MR-Guided SBRT
- Volunteers
- 40 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Prostate Cancer, Colorectal Cancer
Implementation Of A Telesurgery Program At A Referral Center For Robotic Surgery
This prospective, single-center pilot cohort study aims to evaluate the feasibility and safety of implementing a robotic telesurgery program in a tertiary academic referral center.
- Trial name
- GTSP (NCT07792109)
- Testing
- Robot-Assisted Telesurgery
- Where
- 3 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prostate Cancer (Adenocarcinoma), Vitamin D on Tumor Response and Inflammatory Markers
Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate Cancer: Elucidating Differential Effects on Immune Function Between Patients With Localized Disease and Those With Metastatic Progression
This study is testing whether fixing vitamin D deficiency in Black/West African men with prostate cancer can strengthen their immune system, improve quality of life, and even slow cancer progression compared to those who remain…
- Trial name
- iCCaRE (NCT07598032)
- Testing
- vitamin D 25(OH)D
- Where
- Nigeria
- Volunteers
- 200 people
- Sponsor
- University of Ilorin Teaching Hospital
Cancer, Urology
Monitoring Treatment Response With Urine and Serum Metabolome Markers in Patients Treated With Novel Hormone Therapy and Have Either Hormone Sensitive Metastatic Prostate Cancer or Disease Progression on Treatment.
80% of patients with newly diagnosed metastatic hormone sensitive prostate cancer have bone metastases. There are mutations that are described with early disease progression when on hormone therapy for prostate cancer.
- Trial name
- Metabolome-PC (NCT07837063)
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Prostate Cancer
Prostate Cancer in UK Prisons: A Retrospective Data Analysis
Prostate cancer is the most common cancer affecting men in the United Kingdom (UK) and is the most common cancer in UK prisons. Early diagnosis is vital because treatment is more effective when the disease is detected at an early…
- Trial name
- PRISON-UK (NCT07870707)
- Where
- United Kingdom
- Volunteers
- 9,007 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Oligometastatic Prostate Cancer
Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
Prostate cancer represents the second most common malignancy in men worldwide. Oligometastatic prostate cancer (OMPC), defined as a transitional state between localized and widespread metastatic disease (≤10 metastatic lesions…
- Trial name
- OMPC-RPM (NCT07490210)
- Testing
- Metastasis-directed radiotherapy, Rezvilutamide + ADT, Radical prostatectomy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Prostate Cancer, Prostate Cancer Metastatic Disease
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases
The goal of this clinical trial is to learn if radiotherapy to the prostate and PET-positive (positron emission tomography) metastasis will lead to radiological response on PSMA-PET (prostate specific membrane antigen-PET).
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic Disease, Prostate Cancer Metastatic to Bone
- Trial name
- RIALTO (NCT07644754)
- Testing
- Radiotherapy to the prostate and to PSMA-PET positive metastases
- Volunteers
- 27 people
- Sponsor
- University Hospital Tuebingen